Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.71 |
| ▸ | ESR1 | P03372 | 3/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.48 |
| ▸ | ALPI | P09923 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | XIAP | P98170 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12285673 | 1.00 | SLC7A5 (0.71) | SLC7A5ESR1ESR2TAAR1SLC6A2 | |
| SCHEMBL8279093 | 1.00 | SLC7A5 (0.71) | SLC7A5ESR1ESR2TAAR1SLC6A2 | |
| SCHEMBL14618135 | 0.89 | SLC7A5 (0.59) | SLC7A5ESR1ESR2TAAR1SLC6A2 | |
| SCHEMBL17913929 | 0.86 | SLC7A5 (0.59) | SLC7A5ESR1ESR2TAAR1SLC6A2 | |
| Tyrosine SCHEMBL28297995 | 0.84 | SLC7A5 (0.92) | SLC7A5ESR1ESR2TAAR1SLC6A2 | |
| Tyrosine SCHEMBL28270669 | 0.84 | SLC7A5 (0.92) | SLC7A5ESR1ESR2TAAR1SLC6A2 | |
| Tyrosine SCHEMBL6374042 | 0.84 | SLC7A5 (0.92) | SLC7A5ESR1ESR2TAAR1SLC6A2 | |
| SCHEMBL18309081 | 0.84 | SLC7A5 (0.67) | SLC7A5ESR1ESR2TAAR1SLC6A2 | |
| Tyrosine SCHEMBL5222909 | 0.84 | SLC7A5 (0.92) | SLC7A5ESR1ESR2TAAR1SLC6A2 | |
| SCHEMBL358908 | 0.83 | SLC7A5 (0.71) | SLC7A5ESR1ESR2TAAR1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023086557-A1 | NUCLEOSIDES FOR THE TREATMENT OF DNA VIRUS INFECTIONS | EMORY UNIVERSITY (US) | 2023-05-19 | — | — | WO | disclosed |
| US-11331331-B2 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | EMORY UNIVERSITY (US) | 2022-05-17 | — | — | US | disclosed |
| WO-2022035843-A1 | TOPOISOMERASE INHIBITORS | NANOMEDICINE INNOVATION CENTER, LLC (US) | 2022-02-17 | — | — | WO | disclosed |
| US-20220016153-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-20 | — | — | US | disclosed |
| US-11197882-B2 | — | — | 2021-12-14 | — | — | US | disclosed |
| US-11147826-B2 | — | — | 2021-10-19 | — | — | US | disclosed |
| US-20210308168-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-07 | — | — | US | disclosed |
| WO-2021159044-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | EMORY UNIVERSITY (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021137913-A2 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2021-07-08 | — | — | WO | disclosed |
| US-20200276219-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-09-03 | — | — | US | disclosed |
| US-20080221137-A1 | Quinazolines useful as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-09-11 | — | — | US | disclosed |
| US-20080221137-A1 | Quinazolines useful as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-09-11 | — | — | US | disclosed |
| EP-1944300-A2 | Prodrugs of aspartyl protease inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20080167305-A1 | QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-07-10 | — | — | US | disclosed |
| US-20080167305-A1 | QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-07-10 | — | — | US | disclosed |
| EP-0933372-B1 | Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors | VERTEX PHARMA (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007075901-A2 | QUINOLIN- 4 - ONE DERIVATIVES AS MODULATORS OF ABC TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007058989-A2 | QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-24 | — | — | WO | disclosed |
| US-4062835-A | LUTEINIZING HORMONE RELEASE ANTAGONISTS | PARKE, DAVIS & COMPANY (US) | 1977-12-13 | — | — | US | disclosed |
| US-4043994-A | New pentapeptides and methods for their production | PARKE, DAVIS & COMPANY (US) | 1977-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11331331-B2 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | ENTPD1, NME2, NME1 | SLC7A5 1217/4885ESR1 1471/4885ESR2 2177/4885 |
| US-20210308168-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, PRPF4, HPRT1 | SLC7A5 1399/4885ESR1 2065/4885ESR2 1956/4885 |
| US-11147826-B2 | — | SNRPE, NME2, NME1 | SLC7A5 2167/4885ESR1 742/4885ESR2 1307/4885 |
| US-20220016153-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | ENTPD1, NME2, NME1 | SLC7A5 1217/4885ESR1 1471/4885ESR2 2177/4885 |
| US-20080167305-A1 | QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS | KCNQ1, KCNQ2, KCNQ5 | SLC7A5 818/4885ESR1 4783/4885ESR2 4413/4885 |
| US-20200276219-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | ENTPD1, NME2, NME1 | SLC7A5 1217/4885ESR1 1471/4885ESR2 2177/4885 |
| US-11197882-B2 | — | SNRPE, NME2, NME1 | SLC7A5 2167/4885ESR1 742/4885ESR2 1307/4885 |
| US-20080221137-A1 | Quinazolines useful as modulators of voltage gated ion channels | KCNQ1, KCNQ2, KCNQ5 | SLC7A5 818/4885ESR1 4783/4885ESR2 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.